An epidemiological study of patients with breast cancer in Northern Iran, between 2006 and 2015

WCRJ 2016; 3 (4): e803
DOI: 10.32113/wcrj_201612_803

Costs and quality of genomics tests in the oncology field

WCRJ 2016; 3 (4): e801
DOI: 10.32113/wcrj_201612_801

A cost-effectiveness method for detection of ABL mutations in patients who developed Imatinib resistance

WCRJ 2016; 3 (4): e799
DOI: 10.32113/wcrj_201612_799

Recent evolutions on cancer clinical aspects and therapeutics approach. Naples (Italy) 11-12 July 2016

WCRJ 2016; 3 (4): e790
DOI: 10.32113/wcrj_201612_790

Nutraceutical agents with hepatoprotective effects in cancer patients

WCRJ 2016; 3 (4): e788
DOI: 10.32113/wcrj_201612_788

Commentary – Beliefs and preferred communication channels toward patients with cancer in Jordan

WCRJ 2016; 3 (4): e786
DOI: 10.32113/wcrj_201612_786

Beliefs and preferred communication channels toward patients with cancer in Jordan

WCRJ 2016; 3 (3): e753

Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings

WCRJ 2016; 3 (3): e748

Over expression of the fatty acid synthase is a strong predictor of poor prognosis and contributes to glucocorticoid resistance in B-cell acute lymphoblastic leukemia

WCRJ 2016; 3 (3): e746

Evaluation of clinical and economic impact of pharmacogenomics testing in taxanes-based therapy

WCRJ 2016; 3 (3): e744

• Newer
• 1
• …
• 32
• 33
• 34
• 35
• 36
• 37
• 38
• 39
• 40
• 41
• 42
• …
• 48
• Older